Edward J. Dulac III - 05 Jan 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Financial Officer
Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
05 Jan 2026
Net transactions value
-$58,751
Form type
4
Filing time
07 Jan 2026, 16:02:56 UTC
Previous filing
25 Jul 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dulac Edward J III EVP, Chief Financial Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE James Basta, attorney-in-fact 07 Jan 2026 0001821530

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale $58,751 -6,379 -6% $9.21 99,683 05 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.